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HEREDITARY COLORECTAL CANCER BLUES 
 
 
”You are old father William,” the young surgeon said, 
”And your colon from polyps is free” 
”Yet most of your siblings are known to be dead- 
A really bad family tree.” 
 
 
”In my youth,” Father William replied with a grin, 
I was told that a gene had mutated, 
That all who carried this dominant gene 
To polyps and cancer fated”. 
 
 
”I sought advice from a surgical friend, 
Who sighed and said-”Without doubt 
Your only escape from an untimely death 
Is to have your intestine right out.” 
 
 
”It seemed rather bad luck – I was only nineteen –  
So I went and consulted a quack, 
Who took a firm grip on my dominant gene 
And promptly mutated it back” 
 
 
”This,” said the surgeon, ”is something quite new 
And before we ascribe any merit 
We must see if the claims of this fellow are true, 
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2 GENERAL INTRODUCTION  
 
Abbreviations 
AMS  Amsterdam criteria 
AMS I  Amsterdam criteria I 
AMS II Amsterdam criteria II 
BRCA1/2 Breast cancer gene 1/2 
CRC  Colorectal cancer 
AFAP  Attenuated familial adenomatous polyposis 
FAP  Familial adenomatous polyposis 
FS  Flexible sigmoidoscopy 
HBOC  Hereditary breast- and breast-ovarian cancer 
HNPCC Hereditary non polyposis colon cancer 
IHC  Immunohistochemical analysis 
LOCRC Late onset colorectal cancer 
MLH1  Mutator L homologue gene, MMR gene 
MSH2  Mutator S homologue gene 2, MMR gene 
MSH6  Mutator L homologue gene 6, MMR gene 
PMS1-2 Human homologue of yeast postmeiotic segregation gene 1 and 2, MMR gene 
MMR  Mismatch repair 
MSI  Microsatellite instability 
MSI-H  MSI-high 
MSL-L MSI-low 
PCR  Polymerase chain reaction 
OMIM  (NCBI.nlm.nih.gov/entrez//) 
  * Gene of known sequence 
  # Descripitive entry - phenotype - does not represent a unique locus 








Allele:  Alternative forms of a gene at the same locus on homologous chromosomes 
(Hodgson, et al., 1999). 
 
Constitutive mutation: A mutation that leads to the permanent expression of a gene which is 
normally tightly regulated (Kahl, 1995). 
 
DNA: A nucleotide polymer that carries the genetic information of viruses, bacteria and all 
higher organisms. DNA may occur single-stranded (as in some viral genomes) or double-
stranded (as in organelles and chromosomes of all higher organisms). In double-stranded 
DNA two complementary strands are wound around each other in opposite orientations. The 
two strands are held together by hydrogen bonds between complementary bases (A=T; G≡C). 
The sequence of each strand encodes the genetic information (genetic code) (Kahl, 1995). 
 
Deletion mutation: Any mutation that is generated by the removal of one or more basepairs 
from a particular genome (Kahl, 1995). 
 
Frameshift mutation: An alteration of the reading frame caused by addition or deletion of 
nucleotides in a number not divisible by three. It leads to the synthesis of a missense mRNA 
whose translation usually results in a non-functional protein because the message will be read 
in triplets specifying wrong aminoacids (Kahl, 1995). 
  
Gene: The fundamental physical and functional unit of heredity that carries information from 
one generation to the next. A gene is a specific sequence of nucleotides in DNA (Kahl, 1995). 
 
Genotype:  The individual’s genetic constitution. It describes the alleles at a specific genetic 
locus (Hodgson, et al., 1999). 
 
Index case: The patient whose disease first directed attention to a particular pedigree 
(Passarge, 2001). 
 
Locus: A specific position on a chromosome (Hodgson, et al., 1999). 
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Missense mutation: Any gene mutation in which one or more codon triplets are changed so 
that they direct the incorporation of aminoacids into the encoded protein, which differ from 
the wild type (e.g. UUU, encoding phenylalanine, mutates to UGU, encoding cysteine). The 
replacement of a wild type amino acid by a missense aminoacid in the mutant potentially 
produces an unstable or inactive protein (Kahl, 1995). 
 
Mutation: The process by which genetic material undergoes a detectable and heritable 
structural change, or the result of such a change (Oxford dictionary, 1997). There are several 
definitions of mutations. In this thesis rare genetic variants causing illness are denoted  
mutations, and genetic variants not causing illness denoted polymorphisms. 
 
Mutation testing: Testing for DNA sequence variation (instability). 
 
Nonsense mutation: Any mutation in a coding sequence that converts a sense codon into a 
nonsense codon (stop codon) or a stop codon into a sense codon. As a consequence, the 
encoded protein will be either truncated (premature termination) or too long which in turn 
hampers or abolishes protein function (Kahl, 1995). 
 
Pedigree: The genetic relationship of individuals based on their kinship presented in a figure 
(Passarge, 2001). 
 
Penetrance: A quantitive assessment of the proportion of heterozygotes (gene carriers) who 
express the phenotype (Hodgson, et al., 1999). 
 
Phenotype: The observed result (physical, biochemical or physiological) of the interaction 
between the genotype and the environment (Hodgson, et al., 1999). 
 
Point mutation: A mutation involving a chemical change in only one single nucleotide (Kahl, 
1995). 
 




TNM classification: Staging of cancers according to tumour size (T), lymph node involvement 
(N) and metastases (M). 
 
Wild type: The most frequently occurring phenotype in natural breeding populations. Any 




Incidence: The number of new cases of cancer in a defined population within a specific period 
of time (Cancer in Norway, 2003). 
 
Incidence rate: The number of cases per 100 000 persons per year (Cancer in Norway, 2003). 
 
Positive predictive value: The proportion of truly diseased persons out of all those with 
positive results in the screening tests (Council of Europe, 1974). 
 
Prevalence: Expresses the number of persons in a defined population who are still alive at a 
specific point in time, and that at some time have been diagnosed with cancer (Cancer in 
Norway, 2003). 
 
Sensitivity: The ability of a test to give a positive result in people who truly have the disease; 
a highly sensitive test gives few false negative results (Council of Europe, 1974). 
 
Specificity: The ability of a test to give negative result in people who are free of the diseaes; a 
highly specific test gives few false positive results (Council of Europe, 1974). 
 
Validity: An expression of the relationship between the results of the test and the true situation 








2.1.0 Epidemiology of cancer in Norway 
 
 
2.1.1 All cancers 
The Cancer Registry of Norway is a population-based registry that has systematically 
collected notifications of cancer since 1952. The registry is for practical purposes complete 
from 1953 (Cancer in Norway, 2003). 
 
In 2003, The Cancer Registry of Norway reported 23 307 new cases of cancer, of these 
12 176 were men and 11 131 were women. Cancer incidence (Age adjusted incidence rates) 
has increased about 80% from 1953-1957 till the last complete 5-year period of 1999-2003 
(Cancer in Norway, 2003). Cancer strikes all age groups, but especially the elderly; 85.4 
percent of the cases among men and 77.3 per cent of the cases among women are found in 
people over 55 years of age (Cancer in Norway, 2003). 
 
2.1.2 Hereditary cancer  
High incidence and uneven geographical distribution of hereditary cancer is seen in Nordic 
countries due to founder mutations (Møller, Heimdal et al., 2001; Arason et al., 1998; 
Johannesdottir et al., 1996; Nyström-Lathi et al., 1995; Nyström-Lathi et al., 1996; Holmberg 
et al., 1998). Prevalences of hereditary cancers depend on the clinical criteria employed as 
well as differences between populations. Families with accumulated cancer due to incidental 
clustering or shared environmental factors will influence the estimations. Self referred 
families may have more extreme features and contribute to an overestimation of prevalences. 
Small families may be missed because numbers of affected relatives are low when numbers of 
relatives are low.  
 
2.2.0 Management of hereditary cancer  
 
2.2.1 Familial cancer 
Individuals in families where cancers have occurred previously, have themselves an increased 
risk of developing cancer. They may develop cancer at a young age (30-40 years) and have an 
increased risk of multiple primaries (Watson et al., 1994; Claus et al.,1996; Aarnio et 
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al.,1999; Breast Cancer Linkage Consortium, 1999; Lynch et al.,1999; Møller, Borg et al., 
2001). A family history of cancer may give a rationale for surveillance aiming at early 
diagnosis and improved prognosis, and it may initiate mutation testing (Syngal et al., 1998; 
Järvinen et al., 2000; Møller, Evans et al., 1999; Møller et al., 2002). This has implications for 
the individual persons and financial/capacity implications for the national health system 
(Douglas et al., 1999). 
 
2.2.2 Patients  
Since 1989 patients are either self-referred or referred by their physician to the Section for 
inherited cancer at Rikshospitalt-Radiumhospitalet. They are included according to their 
family history of cancer applying wide clinical criteria (Møller, 1993). According to 
Norwegian legislation (www.Lovdata.no), patients’ relatives have to be informed and invited 
by the index cases to contact the section. Information to the patients is given through genetic 
counselling. Information is also promoted to colleagues in the medical field and through the 
media. Surveillance of patients at risk is coordinated by the section in collaboration with 
relevant specialists. Mutation analyses and testing of tissue is done in collaboration with 
laboratories or pathology departments, respectively. All activity complies with national 
legislation. National and international collaboration and research plays an important part in 
the section’s activities. 
 
2.2.3 Family history 
Patients are mailed a family information questionnaire to fill in information about their closest 
relatives, including names, date of birth, cancer diagnoses, year of diagnosis and hospital 
treatment, and date of death for the deceased. The pedigrees are traced backward and laterally. 
Information on the site and classification of all cancers and polyps and age at diagnosis are 
obtained and verified in the medical files and/or in The Norwegian Cancer Registry whenever 
possible.  
 
2.2.4 Genetic counselling 
During the counselling session the family’s pedigree is commented and the importance of 
having exact information on diagnoses explained. Modes of inheritance and biological insight 
in the mechanisms including Knudson’s two hit hypothesis (Knudson, 1986) are explained 
and information is given on the specific type of inherited cancer running in the family. Risk 
assessments and surveillance options are discussed. 
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Regarding genetic testing, legislation requires pre-, under- and post-test counselling in 
predictive testing.  “Diagnostic”testing will often also be predictive testing as most of the 
hereditary cancers are part of cancer syndromes. A diagnostic test for MMR mutations in a 
female CRC patient, is at the same time a predictive test regarding her risk for endometrial 
cancer. Just as doing a diagnostic test for BRCA1/2 mutations in a patient with breast cancer is 
a predictive test for ovarian cancer. 
 
2.2.5 Mutation testing 
All genetic testing is based on informed consent confirmed in writing. Predictive testing 
requires genetic counselling. Under Norwegian legislation, immunohistochemistry is 
considered as genetic testing, and so is extensive family history to determine risk for inherited 
disorders. 
  
The process of mutation testing is time consuming, costly and there are capacity problems. 
Modes of testing depend on the types of mutations expected. Mutation screening is normally 
first undertaken in one affected family member. If a mutation is found, all other available 
affected members/obligate carriers should be tested to make sure that it is the same mutation 
that causes cancer in the family and that there is not more than one mutation running in the 
family. After this, predictive testing can be offered to unaffected family members. In the 
absence of living affecteds, predictive testing of unaffecteds is inconclusive, except in 
populations with high frequencies of founder mutations. An example is the Norwegian 
founder mutations in the BRCA genes. In a family with a known mutation all test results 
should be verified in a second test from a new blood sample.  
 
2.2.6 Ethics and informed consent 
Under Norwegian legislation, persons at risk should make the initial contact with the proper 
health personnel, and not vice versa. Permission to access the medical files for information is 
obtained in writing from all living persons, and from relatives of the dead ones. Written 
informed consent underlies all requests for tumour specimens and genetic testing. All activity 
reported is approved by the Government as health care. All information is kept in our medical 
files. No results identifying any individual patient are exported from the medical files. No 
research registry is erected. All activity complies with national legislation and includes 
genetic counselling of every person included. 
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2.2.7 Secondary prevention 
Major screening programs are offered as public health service to groups of the population 
thought to be at risk, for example breast cancer screening and screening for cervical cancer. 
Some persons may be at higher risk for cancer than the general population and may require 
closer examinations, this approach is referred to as surveillance (Ponz de Leon, 2002). 
Surveillance should meet the standard requirements for screening, as recommended by WHO: 
There should be a safe, precise and validated screening test. There should be an effective 
treatment or intervention for patients identified through early detection, with evidence of early 
treatment leading to better outcome than late treatment (Wilson, et al., 1968). 
 
Some screening methods are proven to reduce the risk of cancer (CRC) (Järvinen et al., 2000), 
while others are unproven or debatable (cancers of the ovary, endometrium and uroepithelial 
tract) (Aarnio et al., 1999; Dove-Edwin et al., 2002). The surveillance programs are often life 
long and continuity and patient compliance is essential. Results of the surveillance are 
reported back to the medical departments which also monitor the continuity of the program. 
Surveillance guidelines are often a result of national and international collaboration and 
agreements.  
 
2.2.8 Primary prevention 
“Prevention is better than cure” (Ponz de Leon, 2002). For cancers closely related to 
environmental factors (diet/lifestyle), for example lung cancer, prevention is possible by 
removing the causative agent (tobacco smoking). This is primary prevention. Prophylactic 
surgery, like oophorectomy and mastectomy in BRCA mutation carriers, is another example of 
primary prevention. The removal of adenomatous polyps would be secondary prevention, 
while it may be debateable whether a colectomy in a person producing multiple adenomas is 
primary or secondary prevention.  
 
Chemoprevention is one of the most recent strategies in cancer prevention (Wattenberg et al., 
1985), and can be defined as the use of natural compounds or drugs to block, reverse or 






2.3.0 Colorectal cancer 
 
2.3.1 Epidemiology 
In 2003, The Cancer Registry of Norway reported 1035 new cases of colon cancer and 608 
cases of rectal cancer among men. Corresponding numbers were 1261 and 462 for women. 
Colorectal cancer is the most prevalent cancer site for men and women combined and it is the 
second most common cause of death from cancer in Western countries (Cancer in Norway, 
2003). The lifetime risk of developing colorectal cancer is about 4-5%. The incidence of the 
disease is rapidly increasing after the age of 50 (Cancer in Norway, 2003).  
 
The prevalence of polyps reported in the literature varies widely. Polyp incidence increases 
with age, with 34% of those over the age of 50 having a single polyp (Lanspa et al., 1990). 
Adenomatous polyps account for 30 to 50 percent of all polyps and are premalignant lesions 
(Williams et al., 1982). Autopsy studies show a prevalence of adenomas of about 20% at the 
age of 50 years increasing to about 50% after the age of 70 years (Clark et al., 1985; Eide et 




A frequently occurring lesion in the colon is the hyperplastic polyp. If no cellular dysplasia is 
visible in the microscope, a polyp is scored as a hyperpastic polyp (Rex et al., 1992). It is 
commonly believed that hyperplastic polyps, especially those located in the rectum and 
sigmoid colon are benign lesions lacking malignant potential (Ponz de Leon, 2002).   
 
Adenomas 
Colorectal adenomatous polyps are well demarcated lumps of epithelial dysplasia that can be 
classified into three major histological types: tubular, villous and tubulovillous (Ponz de 
Leon, 2002). The adenomas are classified according to the grade of dysplasia as mild, 
moderate or severe. Dysplasia predisposes an organ to cancer development. Adenomas are 
known to be the precursors of sporadic and hereditary colorectal cancer (Vogelstein et al., 
1988; Kinzler et al., 1996). Most CRCs are adenocarcinomas which have developed from 
adenomas. Only about 5% of adenomas become malignant (Wilcox et al., 1987). In sporadic 
cancer the progression from adenoma to cancer takes approximately 10-15 years (Stryker et 
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al., 1987).  Several studies have shown that removal of adenomas may reduce the incidence of 
colorectal cancer (Järvinen et al., 2000; Winawer et al., 1993; Thiis-Evensen et al., 1999). 
 
Hamartomas 
Hamartomas are uncommon polypoid lesions observed in Peutz-Jeghers syndrome and 
Juvenile polyposis. Histologically they show a complex branching pattern of smoothe muscle 
supporting normal lamina propria and glands. These polyps are basically composed of normal 
elements indigenous to the site in which they appear, although their general architecture is 
markedly abnormal (Ponz de Leon, 2000). 
 
Cancers 
Most colorectal carcinomas (95%) are adenocarcinomas and in many cases (10%-20%) may 
show a mucinous component (Bosman, 1995). They may be graded into well, moderately and 
poorly differentiated lesions (Bosman, 1995). Metastasis to regional lymph nodes can be 
detected in 30%-50% of the patients at the time of diagnosis (Sanchez-Cespedes et al., 1999). 
Haematogen metastasis to the liver can be seen in 10%-30% of the patients at diagnosis (Gatta 
et al., 2000). Duke’s staging is commonly used, but the TNM system is now increasingly 
being adapted. Prognosis depends on the stage of disease. 
 
Distal cancers are suggested to be more related to environmental factors and proximal cancers 
more genetically caused (Bonithon-Kopp et al., 1999). There seems to be increasing 
prevalence of proximal cancers with increasing age (Eide et al., 1978; Thiis-Evensen et al., 
1999; Vatn et al., 1982).  
 
2.3.3 Molecular biology 
The majority of CRCs develop from adenomas. The progression from an adenoma to a cancer 
passes through a series of defined histological stages referred to as the adenoma-carcinoma 
sequence (Vogelstein et al., 1988). The colorectal tumour initiation requires several different 






Main events in the adenoma-carcinoma sequence 




 Inactivation of   Accumulation of  Inactivation of 
 APC   other mutations  p53 
    (Kras, DCC,DPC4..) 
 
  ↓   ↓   ↓   
 
Normal  → Small  → Large  → Cancer 
Mucosa   adenoma  adenoma 
 
↑   ↑   ↑ 
 
 
 1 st. rate-limiting step:   2 nd rate-limiting step: 




Two major mechanisms of genomic instability have been identified in sporadic tumour 
progression. The first, known as chromosomal instability (CIN), results from a series of 
genetic changes involving activation of oncogenes such as ki-ras and inactivation of tumour-
suppressor genes such as p53, DCC/SMAD4, and APC (Vogelstein et al., 1988; Fearon et al., 
1990). Large chromosomal alterations such as loss of heterozygosity (LOH), is the 
consequence. The second major mechanism, known as microsatellite instability (MSI) is seen 
in association with HNPCC, but is also found in 12-15% of sporadic CRC (Thibodeau et al., 
1993; Aaltonen et al., 1993). The hallmark of this pathway is a widespread mutation of short 
repetitive DNA sequences known as microsatellites (Gryfe et al., 2001). 
 
Knudson’s two hit hypothesis 
The mismatch repair genes encode protein products recognizing and correcting errors that 
arise when DNA is replicated (Leach et al., 1993, Dunlop et al., 1997). According to the two-
hit model of carcinogenesis, the second event in addition to the inherited mutation is expected 
to be an acquired mutation in the normal allele (Knudson, 1986; Hemminki et al., 1994). If 
both the first and second hits are truncating mutations, the gene product for the gene in 
question should be absent in the tumour cells. This has been demonstrated by 
immunohistochemistry (Thibodeau et al., 1996; de Leeuw et al., 2000).  
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2.3.4 Screening methods 
Faecal occult blood testing (FOBT) 
The test is cheap, non-invasive and considered to be cost-effective (Lieberman, 1995). The 




Single contrast barium enema is inadequate for detecting polyps, but the results improve with 
double-contrast technique. The main limitation of this technique is the impossibility to carry 
out biopsies or polypectomy. 
 
Flexible sigmoidoscopy and colonoscopy 
These tests have the advantage of both detection and removal of premalignant lesions in the 
same procedure. The test has good sensitivity and and high specificity for detection of both 
premalignant lesions and cancers. Colonoscopy screens the whole colon, but requires a larger 
degree of bowel preparation than flexible sigmoidoscopy.  
 
2.3.5 Risk factors 
Age, dietary factors and family history are probably the most important causes of high 
incidence of CRC in the western world. In inflammatory bowel disease, for example patients 
affected by ulcerative colitis are at risk of CRC.  
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Family members of CRC patients are facing a higher risk than the general population. About 
10% of colorectal cancers may be inherited (Houlston et al., 1992), but no more than 2-6 % 
have been demonstrated to be caused by inherited mutations (Houlston et al., 2001). 
 
It is unclear to what extent hereditary factors, shared environment and diet contribute to 
elevated risk. In some cases there might be a combination of genetic and environmental 
factors, as shown with gastric cancer and HNPCC. Gastric cancer has become less frequent in 
MMR mutation carriers, just as it has decreased in the population in general. This is thought 
to be caused by the widespread use of refrigeration of food instead of salting, smoking and 




Primary prevention of CRC is focused on modifying diet (reduced fat and calorie intake and 
increased fruit and vegetable and fibre intake) and increasing exercise. There is some 
evidence of a protective effect of certain nutrients like calcium, selenium and starch 
(NHMRC, 1999). Several studies have demonstrated that aspirin and other non-steroidal anti-
inflammatory drugs (NSAIDs) may give a protection against polyps and cancer (NHMRC, 
1999; Jänne et al., 2000). NSAIDs block cyclooxygenase 1 and 2, which are catalytic 
enzymes involved in the prostaglandin synthesis. Prostaglandines are markedly elevated in 
colorectal cancer tumours (Eberhart et al., 1994). There are several ongoing chemoprevention 
trials. The CAPP1 and CAPP2 studies test whether aspirin and resistant starch make any 
difference to polyp growth in APC mutation carriers who have not had a bowel operation and 
in MMR mutation carriers, respectively (CAPP1/2. www.ncl.ac.uk/capp). 
 
2.4.0 Hereditary colorectal cancer syndromes 
 
The main focus of this thesis is on HNPCC. As a consequence the hamartomatous polyposes 
are only briefly described. 
2.4.1 Hamartomatous polyposes 
These syndromes are rare. They are associated with substantially increased lifetime risks of 
both intestinal and extra-intestinal malignancies. They account for less than 1 percent of 




Gene: PTEN 10q22.3-23.31 OMIM # 158350 
Hamartomas involve the skin, intestine, breast and thyroid gland. There may be CNS 
involvement and increased risk of thyroid and breast cancers. (Eng et al., 1997) 
 
Juvenile Polyposis 
Gene: SMAD4 18q21.1 OMIM # 17490 
Most commonly associated birth defects include malrotation of the midgut, genitourinary 




Gene: STK11 19p13.3 OMIM # 175200 
Hamartomatous polyposis of the gastrointestinal tract and melanin pigmentation of the 
orofacial region. There is an increased risk of gastrointestinal and extragastrointestinal 
malignancies (Lalloo et al., 2005). 
 
2.4.2 Familial adenomatous polyposis (FAP) 
Gene: APC 5q21-22 (8535 bp) OMIM + 175100 
FAP is the best known of colorectal polyposes and was already described in the 1880s. It is an 
autosomal dominant disorder with a population frequency of 1 in 10.000 (Bisgaard et al., 
1994). One third is caused by new mutations. Penetrance is almost 100 percent at the age of 
40. FAP is characterized by hundreds to thousands of adenomas through out the colon. Ninety 
percent of the mutation carriers will have adenomas by the age of 20 (Lalloo et al., 2005). 
Progression of one or more of these adenomas into cancer is inevitable.  
 
FAP patients are at risk of extra colonic manifestations such as adenomas and 
adenocarcinomas of the stomach, the small bowel and the biliary tree, desmoids, osteomas, 
liver tumours, dental abnormalities, epidermal cysts and congenital hypertrophy of the retinal 
pigmeny epithelium (CHRPE). There is an excess of adrenal-, brain- and and papillary thyroid 
cancers.  There seems to be a genotype phenotype correlation.  
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Surveillance: Annual/biannual sigmoidoscopy/colonoscopy from age 11-12 until adenomas 
appear. Optimal timing for colectomy depends on several factors, but in most cases between 
the ages of 16 and 20 years (Ponz de Leon et al., 1999). 
 
2.4.3 MUTYH associated polyposis (MAP) 
Gene:MUTYH 1p34.3-p32.1 (7100bp)  OMIM * 604933 
Recently, homozygous carriers of mutations in the base excision repair gene, MUTYH at 
1p34.1, have been demonstrated to have a predisposition for multiple adenomas and 
colorectal cancer (CRC) causing autosomal recessive inherited disease (Jones et al., 2002). 
The gene encodes a glycolase which is involved in repair of DNA damage caused by reactive 
oxygen species generated during aerobic metabolism (Ames et al., 1991; Halford et al., 2003). 
In variant forms this ability is reduced (Al-Tassan et al., 2002).  
 
Sequence variants in MUTYH are found in different ethnic groups (Jones et al., 2000). Two 
common MUTYH mutations, Y165C and G382D, account for approximately 85% of the 
mutations occurring in individuals of Caucasian ancestry (Jones et al., 2000). Combined data 
from previous studies suggest that about 1% of colorectal cancer cases can be attributed to 
biallelic MUTYH mutations (Halford et al., 2003; Enholm et al., 2003; Fleischman et al., 
2004; Kambara et al., 2004).  
 
Phenotypic expression of the MUTYH mutation in the heterozygous form is not clear. The 
mismatch repair genes also have roles in the removal of oxidative damage (Gu et al., 2002). It 
is demonstrated that the MSH2/MSH6 complex is physically associated with MUTYH at an 
MSH6 binding site and is required to stimulate MUTYH activity (Gu et al., 2002; Bai et al., 
2005). Disruption of the MSH2/MSH6 complex causes HNPCC, and it has been reported that 
MUTYH mutations are associated with colorectal cancer risk and can be associated with the 
clinical features of HNPCC (Kairupan et al., 2005; Ashton et al., 2005).  
 
2.5.0 Hereditary non polyposis colon cancer (HNPCC) (= Lynch syndrome) 
 
HNPCC was originally called the “Cancer Family Syndrome”. The first family published, was 
“Family G” by Aldred Warthin in 1913 (Warthin AS, 1913). The pedigree of the family 
demonstrated an aggregation of cancers of the colon, endometrium and stomach. The family 
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was revisited by Henry Lynch in 1971 (Lynch et al., 1971) who found that the family 
members still were producing an excessive number of cancers and that the cancers appeared 
to be inherited in an autosomal dominant manner. Distinctions were made between two 
hereditary colon cancer syndromes, one including colorectal cancers only and the other 
including colorectal cancer and cancer of the endometrium, ovary, stomach and cutaneous 
sebaceous neoplasms. The syndromes were named Lynch syndrome I and Lynch syndrome II 
respectively, but are now most often referred to as HNPCC. 
 
2.5.1 Clinic 
Because there is no specific clinical sign in the affected patient to make a diagnosis of 
inherited colorectal cancer, recognition of the inherited cause was previously limited to family 
history alone. Features are young age at diagnosis, multiple primaries, synchronous and 
metachronous cancers, proximal CRC and other HNPCC related cancers. HNPCC related 
tumours include colorectal-, endometrial-, ovarian-, stomach-, small bowel-, pancreas-, ureter 
and renal pelvis-, hepatobiliary tract-, and brain tumours (usually glioblastoma), 
sebaceousgland adenomas and keratoacanthomas. 
 
Some syndromes are associated with mutations in the HNPCC genes; 
2.5.1.1 Muir-Torre syndrome 
In this syndrome there is an occurrence of skin sebacous tumours with internal malignancy. 
Sebacous tumours are rare and associated with a high risk of internal cancers. (Rutten et al., 
1999). 
 
2.5.1.2 Turcot syndrome 
In this syndrome there is a co-occurrence of colorectal adenomatous polyposis and primary 
brain tumour. Some cases might be due to autosomal recessive inheritance of two mutations 
in the same HNPCC gene (Hamilton et al., 1995). 
 
2.5.1.3 Neurofibromatosis type 1 
A syndrome has been identified in which children with biallelic DNA-MMR gene mutations 
in MLH1, MSH2, MSH6 or PMS2 develop clinical signs of Neurofibromatosis type 1, in 
particular café au lait spots and early onset neoplasia. The pattern of malignancies is 
characteristic with brain tumours, haematological malignancies in the first decade and 
colorectal cancer in the second decade (Trimbath, et al., 2001).  
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2.5.2 Clinical criteria 
For research purposes, a description of families assumed to have HNPCC was adopted (Vasen 
et al., 1991). The criteria were referred to as the Amsterdam criteria (Amsterdam criteria I) 
and were designed to identify dominantly inherited colorectal cancer with early onset for 
research purposes to identify the underlying mutated genes (Vasen et al., 1991).  
 
Similarly, to achieve higher sensitivity to identify affected families, another set of criteria 
referred to as the Bethesda guidelines were established (Rodriguez-Bigas et al., 1997) and 
later revised (Umar et al., 2004). The Bethesda guidelines were constructed to determine 
which tumours should be examined for MSI.  
 
2.5.2.1 The Amsterdam criteria I: (Vasen et al., 1991). 
At least three relatives in two successive generations with histologicaly verified colorectal 
adenocarcinoma, at least one being diagnosed at <50 years of age. FAP excluded. (All criteria 
must be met) 
 
2.5.2.2 The Amsterdam criteria II: (Vasen et al., 1999). 
Extension of the Amsterdam criteria II by including cancers of the endometrium, duodenum, 
ureter and renal pelvis in addition to colorectalcancers. (All criteria must be 
met). 
 
2.5.2.3 Bethesda criteria: (Rodrigues-Bigas et al., 1997). 
Individuals with cancer in families that meet the Amsterdam criteria I for HNPCC. 
 
Individuals with two HNPCC-related cancers including synchronous or metachronous 
colorectal cancers or associated extracolonic cancers (endometrial-, ovarian-, gastric-, 
hepatobilary-, small bowel-, or upper urinary tract urothelial cancer). 
 
Individuals with colorectal cancer and a first degree relative with colorectal cancer and/or 
HNPCC-related extracolonic cancer and/or a colorectal adenoma, in whom one of the cancers 
was diagnosed before age of 45 and the adenoma was diagnosed before age 40. 
 
Individuals with colorectal cancer or endometrial cancer before age 45. 
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Individuals with right-sided colorectal cancer with an undifferentiated pattern of 
histopathology diagnosed before age 45. 
 
Individuals with signet-ring cell-type colorectal cancer diagnosed before age 45. 
 
Individuals with adenomas diagnosed before age 40 (Familial adenomatous polyposis was 
excluded).  
 
(Meeting any of the criteria listed is sufficient). 
 
2.5.2.4 Revised Bethesda criteria: (Umar et al., 2004). 
Colorectal cancer diagnosed in a patient who is less than 50 years of age. 
 
Presence of synchronous or metachronous colorectal, or other HNPCC – associated tumours, 
regardless of age. 
 
CRC with MSI-H histology diagnosed in a patient who is less than 60 years of age. 
 
Colorectal cancer diagnosed with one or more first-degree relatives with an HNPCC-related 
tumour, with one of the cancers being diagnosed under age fifty. 
 
Colorectal cancer diagnosed with two or more first- or second degree relatives with HNPCC-
related tumours, regardless of age. 
 
(Meeting any of the criteria listed is sufficient). 
 
2.5.3 Pathology 
Rijcken et al (2003) have shown that it seems unlikely that hyperplastic polyps are precursors 
for cancers in patients with HNPCC. In HNPCC, the progression from adenoma to carcinoma 
may take < 3 years (Vasen et al., 1995; Lynch et al., 1996). 
 
CRCs feature mucinous, poorly differentiated tumours and tumours with marked host 
lymphocytic infiltration and lymphoid aggregation at the tumour margin (Shashidharan et al., 
1999). Right sided tumours. Endometrial tumours are of endometroid type (de Leeuw et al., 
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2000). The infiltrating cancers may have a better prognosis compared to sporadic colorectal 
cancers with the same tumour histology (Sankila et al., 1996). 
 
2.5.4 Molecular genetics 
Genes: Mismatch repair genes (Bronner et al., 1994; Fishel et al., 1993; Leach et al., 1993; 
Nicolaides et al., 1994; Papadoupolous et al., 1994; Akiyama et al., 1997; Miyaki et al., 
1997). 
 
MSH2   2p16   (3111  bp) OMIM # 120435 
MLH1  3p21.3  (2484 bp) OMIM # 609310 
MSH6  2p16   (4200 bp) OMIM + 600678 
PMS1  2q31-33  (3063 bp) OMIM + 600258 
PMS2  7p22  (2771 bp) OMIM + 600259 
 
The MMR genes encode protein products which recognize and correct errors that arise when 
DNA is replicated (Leach et al., 1993; Dunlop et al., 1997). The major function of the DNA 
mismatch repair system is the elimination of base-base mismatches and insertion-deletion 
loops. MSH2 complexes with MSH6 and forms the hMutSα heterodimer which recognizes 
base-base mismatches. MLH1 and PMS2 form the hMutLα heterodimer which plays a role in 
coordinating the mismatch repair system. 
 
Most of the MMR mutations found in humans have been detected in either MSH2 or MLH1 
genes. The majority of mutations in MLH1 and MSH2 are evenly distributed, with some 
clustering in MSH2 exon 12 and MLH1 exon 16 (Peltomaki et al., 1997). Available evidence 
suggests that PMS1, PMS2 and MSH6 account for less than 5% of constitutional mutations 
detected in HNPCC families (Peltomaki et al., 1997). All classes of DNA variations may 
cause HNPCC; nonsense, frameshift, splice, missense, point mutations, exon 
deletions/duplications and rearrangements. Most MSH2 alterations consist of frameshift 
(60%) or missense mutations (31%) (Peltomaki et al., 1997). 
 
Whether or not missense mutations are disease-associated has become a practical clinical 
problem. Only the availability of a functional test will be able to determine the pathogenicity 
of the mutation. Functional tests for MLH1 missense mutations have been done, 
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demonstrating that the majority of the investigated missense mutations had impaired repair 
function and were likely to be causative for HNPCC (Shimodaira et al., 1998; Guerette et al., 
1999). In one of our papers we demonstrate that an MSH2 missense mutation is disease 
associated (Stormorken et al., 2003). 
  
One to two percent of all CRC occurs in MMR mutation carriers (Dunlop et al., 2000; 
Salovaara et al., 2000).  
 
2.5.4.1 Probability for MMR mutations  
Fulfillment of Amsterdam criteria I, number and mean age of colorectal cancers in the family 
and presence of endometrial cancer were entered into a multivariate logistic regression model 
to calculate probability for the affected patient to carry a MLH1 or MSH2 mutation (Wijnen, 
Vasen et al., 1998). The probability for MSH6 mutation was not calculated. A family with a 
high mean age of diagnosis and without any cases of endometrial cancer has a low probability 
of harbouring an MMR mutation. 
 
2.5.5 Microsatellite instability (MSI) 
MSI is defined as presence of extra alleles at a microsatellite when compared with normal 
DNA from the same individual and results from frameshift mutations at repeats (Lalloo et al.,  
2005). 
 
MMR genes correct mispairing that occurs during DNA replication. If the MMR system is 
dysfunctional, numerous replication errors (RER) accumulate in the genome. The majority of 
HNPCC tumours show MSI.  
 
About 15-20 % of sporadic cancers demonstrate MSI. The figure is even higher in early-onset 
sporadic colon malignancy. This is usually due to hypermethylation of the MLH1 promotors, 
thus MSI alone in colon cancer is a poor predictor of HNPCC. MSI in sporadic rectal cancers 
is rare, and is a good marker of HNPCC (Cunningham et al., 1998). MSI is also seen in about 







The presence of MMR gene products may be analysed by using antibodies against MLH1, 
MSH2, MSH6 and PMS2 proteins. Staining can be performed on sections from formalin-
fixed, paraffin embedded tissue blocks containing tumour tissue and normal adjacent mucosa.   
 
The MLH1, MSH2, MSH6 and PMS2 staining patterns in normal cells are nuclear. 
Expression is particularly prominent in the epithelium of the digestive tract as well as in testis 
and ovary. In the intestine, expression is confined to the replicating compartment, i.e the 
bottom half of the crypts (Hamilton et al., 2000). Staining is evaluated using normal epithelial 
cells, stromal cells or lymphocytes in the same slide as controls. Loss of nuclear staining in 
tumour cells and normal staining of the internal control indicates loss of expression of MMR 
protein. 
 
Tumours lacking normal MSH2 protein may also lack MSH6 protein (de Leeuw et al., 2000; 
Wagner et al., 2001; Schweizer et al., 2001; Stormorken et al., 2001; 2003; 2005).  This is 
most likely the result of abrogation of the MutSα complex formed by the MSH2 and MSH6 
proteins and acting as a mismatch recognition factor (Schweizer et al., 2001). It has been 
shown that MSH2 has two interaction regions with MSH6 (Guerette et al., 1998) and that the 
MSH6 protein is unstable in the absence of MSH2 (Chang et al., 2000; Marra et al., 1998). 
Thus, absence of MSH6 protein may be expected if no normal MSH2 protein is present.  
 
PMS2 protein forms a heterodimer with the MLH1 protein. Absence of MLH1 protein due to 
a germline mutation also leads to loss of the PMS2 protein.  
 
Polyps are “normally” seen in adult persons. In MMR mutation carriers, studies have shown 
that about 75% of adenomas detected in HNPCC families showed MSI as well as loss of 
protein (Iino et al., 2000). Still, some adenomas may show presence of all three proteins. This 
may indicate that the adenoma formation is not caused by the inactivation of the second allele 
(confer the two-hit model), but that they may have an increased propencity to become 
malignant in MMR mutation carriers. The “second hit” makes the polyp malignant, it may not 






MLH1 promotor hypermethylation and lack of expression of this protein has been shown in 
10-15 % of sporadic colorectal cancers and occurs in about 15 % of sporadic endometrial 
cancers as well (Thibodeau et al., 1998; Kuismanen et al., 2000; Esteler et al., 1998). It is 
strongly associated with increasing age (Schweizer et al., 2001). 
 
Biallelic inactivation of MLH1 expression is caused by epigenetic inactivation of both parent 
copies of the gene. It has been shown that MLH1 promotor methylation is associated with 
sporadic MSI cancers that lack MMR gene mutation and that methylation is not a common 
second hit mechanism in inactivation of MMR genes in HNPCC cancers (Veigl et al., 1998; 
Wheeler et al., 2000). 
 
2.5.8 Mutation testing 
Demonstration of disease-predisposing variations in DNA-base sequences is instrumental to 
identify high risk persons. Due to the heterogeneity of the mutation spectrum in MMR genes, 
complete mutation analysis is expensive, time consuming and only available in specialized 
centres. Once a mutation is detected in an affected family member it is possible to offer 
predictive testing to other family members.  
 
2.5.9 Genotype-phenotype correlations and cancer risk 
In a previous study (Vasen et al., 2001) MSH2 mutation carriers were found to have a 
significantly higher risk of developing endometrial cancer and cancer of the urinary tract than 
MLH1 mutation carriers. The risk of developing cancer of the stomach, ovary and brain was 
also higher in the MSH2 mutation carriers than in the MLH1 mutation carriers, but the 
difference was not statistically significant in this study.  
 
We have previously shown a predominance of endometrial carcinoma and higher age at 
diagnosis in families with an MSH6 mutation compared with families with an MLH1 or MSH2 
mutation (Wijnen et al., 1999).  
 
Mean percentage lifetime risk (by age 70 years) of developing any HNPCC related tumour 
was 76% for MLH1 mutation carriers, 80% for MSH2 mutation carriers and 73% for MSH6 
mutation carriers (Hendriks et al., 2004). The latter has a higher mean age at onset. For all 
mutations a higher risk of developing CRC is seen in male mutation carriers.  
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It has been shown that HNPCC tumours often have a better prognosis compared to sporadic 





Genotype-phenotype correlations (Wijnen et al., 1999; Vasen et al., 2001; Hendriks et 
al., 2004). 
 
Gene Mean percentage cancer 
risk at 70 yrs  
Mean age at diagnosis  
All HNPCC related tumours   
MLH1 76 (62-85)  
MSH2 80 (70-86)  
MSH6 73 (60-82)  
CRC in men   
MLH1 65 (39-80) 43 (16-81)* 
MSH2 63 (49-73) 44 (16-90)* 
MSH6 69 (42-83) 55 (26-84) 
CRC in women   
MLH1 53 (33-66) 43 (16-81)* 
MSH2 68 (43-82) 44 (16-90)* 
MSH6 30 (12-44) 57 (41-81) 
Endometrial carcinoma   
MLH1 27 (14-38) 48 (+/-5.5)** 
MSH2 40 (21-54) 49 (+/-6.6)** 
MSH6 71 (50-83) 54 (43-65) 
 
*men and women in total, numbers from Vasen et al., 2001 

















Examples of pedigrees: 
 
○ = female ● = affected female □ = male ■ = affected male     ⁄ = diseased 





































Persons at risk are included in lifelong screening programs. Dedicated registries monitor the 
surveillance programs in some centres, giving the opportunity of assessing effects of 
intervention. 
 
In HNPCC families without an identified mutation, assuming autosomal dominant inheritance 
with high penetrance, all first degree relatives of affecteds are assumed to have about one in 
three lifetime risk of HNPCC related cancer and are offered surveillance programs. When 
mutation testing is available, predictive testing should be offered and those not carrying the 
family mutation excluded from follow-up.  
 
According to the guidelines proposed by the International Collaborative Group on HNPCC 
(www.insight-group.org), surveillance of the colon and endometrium is recommended for all 
mutation carriers. Surveillance of other sites is based on the phenotypes of the disease in each 
individual family. Family members may develop cancers at sights that are not included in the 
surveillance programs, demanding alertness from the physicians handling the patients. 
 
2.5.11 Screening for colorectal cancer 
Early detection and removal of adenomas or carcinomas may prevent colorectal cancer deaths 
(Järvinen et al., 2000). HNPCC patients appear to develop intestinal polyps at about the same 
frequency as the general population, but at a younger age (Vasen et al., 1995). The adenomas 
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are shown to be more likely to undergo malignant transformation and to display an 
accelerated adenoma to carcinoma transition as compared to the adenomas seen in the general 
population (Lynch et al., 1977; Jass et al., 1992).  
 
According to the prevention guidelines of the International Collaborative Group on HNPCC 
(www.insight-group.org) total colonoscopy is the method of choice. Until 1996 the 
recommended interval between examinations was three years, after this, families suspected of 
HNPCC are recommended screening every two years from 25-30 years of age. If tubular 
adenoma(s) are detected or if the examination has not been complete a new colonoscopy 




2.5.12 Extracolonic screening 
Endometrium 
Annual or biannual transvaginal sonography. The value of this surveillance is unknown  
A liberal approach toward prophylactic hysterectomy for women older than 50 years with a 
truncating MSH6 mutation has been advocated (Hendriks et al., 2004). 
 
Gastric Cancer 
Screening by endoscopy has been suggested, but is unproven and should only be discussed in 
families with a high incidence of this type of cancer. 
 
Uroepithelial tract 
Surveillance of the urinary tract should be considered in MSH2 mutation carriers. (Vasen et 
al., 2001). The recommended protocol includes cytologic examination of the urine and 
sonography starting at the age 30-35 years old at 1-2 years intervals (www.insight-group.org). 
But one must be aware that sensitivity and specificity of these tests are yet unknown (Sijmons 
et al., 1998). 
 
2.5.13 Treatment 
Demonstration of mutation may give valuable information for selection of treatment 
modalities of HNPCC related tumours, because MMR deficient tumours seem to be resistant 
to certain chemotherapeutic agents (Sedwick et al., 1999).  
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2.6.0 Late onset hereditary gastrointestinal cancer (LOCRC) 
 
The affecteds in the families tend to have onset of cancer at an older age. Inclusion criteria are 
four or more HNPCC related cancers in one lineage all diagnosed over 50 years of age 
(NGICG, 2005). The genetic basis of LOCRC is unknown and the adenoma-carcinoma 
sequence is not thought to be accelerated. They may be well served with colonoscopy every 









































3 BACKGROUND AND AIMS OF THE STUDY 
 
Hereditary non-polyposis colorectal cancer may be caused by mutations in the mismatch 
repair genes MLH1, MSH2, MSH6 or PMS2. Family history (Amsterdam criteria) and 
immunohistochemistry in tumour specimens can be used as pre-screening tools to select 
families for mutation screening. Mutation carriers have an increased risk of developing 
colorectal- and other HNPCC related cancers. Persons at risk are invited to participate in 
surveillance programs aiming at early diagnosis and prevention of cancer.  
 
The aim of this thesis was to Ddescribe hereditary colorectal cancer among Norwegian 
patients by using family history as the initial approach. We compared genotype-phenotype 
correlations and the cumulative risks for cancer. We wished to Ddevelop and validate 
methods used to select families at risk and to estimate the prevalences of such families. 
Finally we wanted to report the findings at prospective colonoscopic follow-up in hereditary 
CRC kindreds.   
 
The clinical phenotypes of mutations in the MLH1, MSH2 and MSH6 genes and 
consequences for surveillance. 
The risk of developing colorectal, endometrial and other cancers between families with 
various MMR-gene mutations might show genotype-phenotype variation. Survival analysis 
was used to calculate the cumulative risk of developing cancer in the various subsets of 
relatives. (Papers I, II) 
 
The role of missense or inframe mutations in HNPCC. 
Whether or not missense or inframe mutations are disease-associated has become a practical 
clinical problem. Demonstration of disease-predisposing mutations is instrumental to select 
high-risk persons for clinical examinations. One large kindred with an inframe MSH2 codon 
N596 deletion was examined with IHC and LOD score was computed to demonstrate that the 
mutation was linked to disease. (Paper III) 
 




Instability of microsatellite repeat sequences has been observed in colorectal carcinomas and 
in extracolonic malignancies, predominantly endometrial tumours, occurring in the context of 
HNPCC. We wished to investigate whether MSI in endometrial hyperplasia and altered 
protein staining for the MMR genes indicated that inactivation of MMR genes is an early 
event in endometrial tumourigenesis. (Paper IV). 
 
The prediction of MMR gene defects using family history and IHC as pre-screening 
methods. 
According to the two-hit model of carcinogenesis, the second event in addition to the 
inherited mutation is expected to be an acquired mutation in the normal allele, leaving the 
gene product of the gene in question absent in the tumour cells. This has been demonstrated 
by immunohistochemistry. We validated the sensitivity, specificity and positive predictive 
value of immunohistochemistry compared with various clinical criteria, to select HNPCC 
kindreds for mutation testing. (Papers V, VI).  
 
The role of MUTYH mutations in HNPCC and late onset familial colorectal cancer. 
Recently, carriers of biallelic mutations in the base excision repair gene MUTYH, have been 
demonstrated to have a predisposition for multiple adenomas and colorectal cancer. In this 
paper we investigated the role of MUTYH mutations in families having been examined with 
IHC without showing loss of MMR protein and the role of heterozygous carriers of MUTYH 
mutations. (Paper VII). 
 
Estimated prevalences of hereditary cancer and need for surveillance. 
Surveillance of persons at increased risk is economically cost-beneficial if inherited cancers 
are prevented or cured by health care programs offered. Continued surveillance of an 
unnecessary high number leads to unjustified cancer worry, is costly and occupies health care 
facilities. Genetic workup was done in all persons (n=7224) attending the NORwegian 
Colorectal Cancer Prevention (NORCCAP) trial in Telemark county. Prevalence of hereditary 
cancer and need for surveillance was estimated. (Paper VIII). 
 
Prevention of colorectal cancer by colonoscopic surveillance in families with hereditary 
colorectal cancer. 
Persons at risk for CRC have the last years been subjected to follow-up by colonoscopy in 
many centres. Altogether 1133 healthy individuals were included according to their family 
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history of colorectal cancers and were prospectively followed with colonoscopies. We here 


































4. SUMMARY OF PAPERS 
The present thesis is based on the following papers:  
 
 I. MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation 
carriers. A study of 138 HNPCC families. 
HFA Vasen, A Stormorken, FH Menko, FM Nagengast, JH Kleibuker, G Griffioen, 
BG Taal, P Møller and JT Wijnen. 
Journal of Clinical Oncology 2001; 19 (20):4074-4080. 
 
We compared the risk of developing colorectal, endometrial and other cancers 
between families with various MMR-gene mutations. Clinical and pathologic data 
were collected from 138 families with HNPCC. Survival analysis was used to 
calculate the cumulative risk of developing cancer in the various subsets of relatives. 
 
Mutations were identified in 79 families: 34 in MLH1, 40 in MSH2 and five in MSH6. 
The lifetime risk of developing cancer at any site was significantly higher for MSH2 
mutation carriers than for MLH1 mutation carriers (P<.01). The risk of developing 
colorectal or endometrial cancer was higher in MSH2 mutation carriers than in MLH1 
mutation carriers, but the difference was not significant (P=.13 and P=.057, 
respectively). MSH2 mutation carriers were found to have a significantly higher risk of 
developing cancer of the urinary tract (P<.05). The risk of developing cancer of the 
ovaries, stomach, and brain was also higher in the MSH2 mutation carriers, but the 
difference was not statistically significant. 
 
Pending large prospective studies, an extension of the current surveillance program in 
MSH2 mutation carriers with the inclusion of the urinary tract should be considered. 
 
II. Cancer risk in Hereditary nonpolyposis colorectal cancer due to MSH6 
mutations: Impact on counseling and surveillance.  
YMC Hendriks, A Wagner, H Morreau, F Menko, A Stormorken, F Quehenberger, L 
Sandkuijl, P Møller, M Genuardi, H van Houwelingen, C Tops, M van Puijenbroek, P 
Verkuijlen, G Kenter, A van Mil, H Meijers-Heijboer, GB Tan, MH Breuning, R 
Fodde, JT Wijnen, AHJT Bröcker-Vriends and H Vasen. 
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Gastroenterology 2004; 127(1):17-25. 
 
The cumulative cancer risks between MSH6 and MLH1/MSH2 mutation carriers were 
compared. MSI analysis and IHC were performed in the available tumours. 
 
A total of 146 MSH6 mutation carriers were identified. The cumulative risk for 
colorectal carcinoma was 69% for men, 30% for women, and 71% for endometrial 
carcinoma at 70 years of age. The risk for all HNPCC-related tumours was 
significantly lower in MSH6 than in MLH1 or MSH2 mutation carriers (P = 0.002). In 
male carriers, the risk for colorectal cancer was lower in MSH6 than in MLH1 or 
MSH2 mutation carriers, but  the difference was not significant (P = 0.0854). MSI 
analysis in colorectal tumours had a sensitivity of 90% in predicting a mutation in 
MSH6. 
 
We recommend starting colonoscopic surveillance in female MSH6 mutation carriers 
from age 30 years. Prophylactic hysterectomy might be considered in carriers older 
than 50 years. 
 
III. The inframe MSH2 codon 596 deletion is linked with HNPCC and associated with 
lack of MSH2 protein in tumours. 
A Stormorken, W Müller, A Lindblom, K Heimdal, S Aase, IM Bowitz Lothe, T 
Norèn, JT Wijnen, G Möslein and P Møller. 
Familial Cancer 2003; 2(1): 9-13.  
 
Whether or not missense or inframe mutations are disease-associated has become a 
practical clinical problem. One large kindred applying for health care had an N596del 
mutation in the MSH2 gene.  
 
Information on the site and classification of all cancers and age at diagnosis was 
obtained and verified. The mutation was tested for in all available affected persons. All 
available tumour material was examined by IHC for presence of MLH1, MSH2 and 
MSH6 gene products. Lod scores were computed by the MLINK programme.  
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All branches met the revised Amsterdam criteria, while only one branch met the 
original Amsterdam criteria. We demonstrated that the mutation was linked to disease 
with a lod score of 5.7 in the family, and all but one examined tumours lacked the 
MSH2 protein. The family demonstrated that the N596del mutation in the MSH2 gene 
is highly penetrant and confers the usual expression of the gene. Presence or absence 
of mutation is now being used for predictive genetic testing in the kindred. 
 
IV. Prediction of a mismatch repair gene defect by microsatellite instability and 
immunohistochemical analysis in endometrial tumours from HNPCC patients. 
WJF de Leeuw, JW Dierssen, HFA Vasen, JT Wijnen, GG Kenter, H Meijers-
Heijboer, A Brocker-Vrieds, A Stormorken, P Møller, F Menko, CJ Corneliosse and H 
Morreau. 
Journal of Pathology 2000; 192:328-335.  
 
Instability of microsatellite repeat sequences has been observed in colorectal 
carcinomas and in extracolonic malignancies, predominantly endometrial tumours, 
occurring in the context of HNPCC. 
 
This study showed that all the endometrial carcinomas (n=12) from carriers of MLH1 
and MSH2 germline mutations demonstrated an MSI-high phenotype involving all 
types of repeat markers, while in endometrial carcinomas from MSH6 mutation 
carriers, only 4 out of 11 demonstrated an MSI-high phenotype. Interestingly, an MSI-
high phenotype was found in endometrial hyperplasia from MSH2 mutation carriers, in 
contrast to hyperplasia from MLH1 mutation carriers, which exhibited an MSI-stable 
phenotype. Instability of only mononucleotide repeat markers was found in both 
endometrial carcinomas and hyperplasias from MSH6 mutation carriers. In 29 out of 
31 endometrial tumour foci, combined MSI and immunohistochemical analysis of 
MLH1, MSH2 and MSH6 could predict the identified germline mutation. The 
observation of MSI in endometrial hyperplasia and of altered protein staining for the 
MMR genes supports the idea that inactivation of MMR genes is an early event in 
endometrial tumourigenesis.  
 
Assessment of altered protein staining combined with MSI analysis of endometrial 
tumours might direct the mutational analysis of MMR genes.  
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V. Prediction of the outcome of genetic testing in HNPCC kindreds using the revised 
Amsterdam criteria and immunohistochemistry. 
A Stormorken, W Müller, B Lemkemeyer, J Apold, JT Wijnen, R Fodde, G Möslein 
and P Møller.  
Familial Cancer 2001; 1:169-173. 
 
Fifty-six families that were previously tested for MLH1, MSH2 and MSH6 mutations 
were selected for a pilot study. All pedigrees were extended and verified and the 
families were scored according to the Amsterdam I and Amsterdam II criteria. The 
probabilities for MLH1 and MSH2 mutations were calculated by logistic regression. In 
addition, all available tumour material from indexed family members was examined 
by IHC for the presence of the three gene products.  
 
Three out of seven families where the mutation could be identified complied with the 
Amsterdam criteria I, while seven met the Amsterdam criteria II. All families carrying 
an MLH1 or MSH2 mutation had >15% calculated probability of finding a mutation. 
Tumours from all seven mutation carriers lacked the immunohistochemical expression 
of the corresponding MMR gene.  
 
The results indicate that the Amsterdam criteria II in combination with 
immunohistochemistry of the mismatch repair proteins in tumours may be a cost-
effective approach to select families for mutation analysis. 
 
VI. Immunohistochemistry identifies carriers of mismatch repair gene defects 
causing Hereditary nonpolyposis colorectal cancer. 
A Stormorken, IM Bowitz-Lothe, T Norèn, E Kure, S Aase, JT Wijnen, J Apold, K 
Heimdal, P Møller 
Journal of Clinical Oncology 2005; 23:4705-4712.  
 
After encouraging results in the pilot study we decided to expand the study. Pedigrees 
from 250 families were extended, cancer diagnoses were verified and families were 
classified according to the Amsterdam and the Bethesda criteria. Tumour specimens 
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were examined for the presence of MLH1, MSH2 and MSH6 proteins. Mutation 
analyses were performed in blood samples from the same patients.  
 
Blood samples from affected index persons in 181 families and tumour specimens 
from 127 of these were obtained. Thirty tumours lacked one or more gene products. 
Sensitivity of IHC to detect mutation carriers was 100%, specificity was 82% and 
positive predictive value was 85%. Sensitivities, specificities and positive predictive 
values for the Amsterdam criteria were 82%, 8% and 45%, respectively, and for the 
Bethesda criteria were 100%, 0% and 48%, respectively. Distribution of mutations 
was MLH1 = 4, MSH2 = 11 and MSH6 = 4.  
 
Wide clinical criteria to select HNPCC kindreds, followed by immunohistochemistry 
of tumour material from one affected in each family had high sensitivity and 
specificity to predict MMR mutations. 
 
VII. MUTYH mutations do not cause HNPCC or late onset familial colorectal cancer. 
 A Stormorken , KM Heintz , PA Andresen, E Hovig, P Møller. 
 Hereditary cancer in clinical practice 2006;4(2):90-93. 
 
Reports on MYH mutations were reviewed and compared to our local findings. Our 
findings were that heterozygous MYH mutations did not cause familial clustering of 
colorectal cancer, and one homozygous carrier in our series of CRC patients did not 
meet the criteria for FAP or AFAP.  
 
We conclude that MYH, when mutated, causes a rare recessively inherited disorder 
including colorectal- and duodenal cancers, which is phenotypically different from 
FAP. It is not verified that heterozygous carriers of MYH mutations have an increased 
risk of cancer. 
 
VIII. Estimated prevalences of hereditary cancers and need for surveillance in a 
Norwegian county, Telemark. 
A Stormorken, G Hoff, J Norstein, IM Bowitz-Lothe, E Hanslien, E Grindedal, P 
Møller. 
Scandinavian Journal of Gastroenterology 2006; 41:71-79. 
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All persons attending the NORwegian Colorectal Cancer Prevention (NORCCAP) 
trial in Telemark, were interviewed about cases of cancer in the family. Diagnoses 
were verified, pedigrees constructed and families classified according to preset criteria 
aiming at identifying hereditary cancer. Mutation analyses were performed in kindreds 
at risk for breast cancers when possible. Immunohistochemistry of tumors in assumed 
inherited colorectal cancer families was undertaken. 
 
The screening examination was attended by 7224 persons among whom 2866 had 
cancer in the family. Of these, 2479 had no suspicion of any known inherited cancer 
syndrome. Family information questionnaires were mailed to 387 persons and returned 
by 191. Sixty-four of these 191 met the clinical criteria for familial cancer by family 
history after verification of diagnoses. Observed prevalences for being at risk for 
HBOC or HNPCC were 2.8‰ and 0.77‰ respectively. 
 
The obtained number of colonoscopies and mammograms per year to serve those who 
needed so, were limited and reduced from 2866 with a family history of cancer to 64 
proven cases by clinical genetic work-up. Continued surveillance of an unnecessary 
high number leads to unjustified cancer worry, is costly and occupies health care 
facilities. Genetic work-up is a one-time job, reduces input numbers to surveillance 
programs, provides a starting point for mutation testing and is economically cost-
beneficial if inherited cancers are prevented or cured by health care programs offered.  
 
IX. Prevention of colorectal cancer by colonoscopic surveillance in families with 
hereditary colorectal cancer. 
A Stormorken, N Clarke, E Grindedal, L Mæhle, P Møller 
Scandinavian Journal of Gastroenterology 2006: Accepted 
  
 Persons at risk for colorectal cancers (CRC) were prospectively followed with 
colonoscopies. In this paper we report the observed results of our activity over the last 
15 years. 
 
Altogether 1133 individuals were included and observed for a total of 3474 follow-up 
years from the first to the last colonoscopy initiated by our activity. MMR mutations 
 49
were demonstrated in 6.5%.  A total of 1383 polyps were removed, 72% were less 
than 5mm in diameter. Findings were scored as hyperplastic (n=887), adenomas with 
mild to moderate dysplasia (n=460), adenomas with high grade dysplasia (n=30) and 
cancers (n=6). Two cancers were observed after first colonoscopy, compared to 2.6 
expected by chance and more than 20 expected under a hypothesis of dominantly 
inherited diseases in the families.  Observed annual incidence rates for adenomas were 
similar in all groups, while in the mutation carriers they more frequently had 
progressed to severe dysplasia or infiltrating cancer.  
 
A simple explanation for the combined findings may be that all selected families had a 
similar tendency to produce adenomas, while mutation carriers more frequently 
demonstrated dysplasia/cancer in the adenomas. The low annual incidence rates for 























5 GENERAL DISCUSSION 
 
The papers support the views that 
• Genotype-phenotype correlations might influence the need for a more tailor made 
surveillance protocol.  
• Amsterdam criteria II in combination with immunohistochemistry of the mismatch 
repair proteins in tumours may be a cost-effective approach to select families for 
mutation analysis.  
• MUTYH mutations do not cause HNPCC or late onset familial colorectal cancer. 
• Genetic work-up reduces input numbers to surveillance programs.  
• The low annual incidence rates for CRC in our study indicated that the removal of 
adenomas may have prevented cancers. 
 
5.1 Genotype-phenotype correlations might influence the need for a more tailor 
made surveillance protocol.  
In collaboration with the Leiden group in the Netherlands we demonstrated substantial 
differences in cancer risks between MLH1, MSH2 and MSH6 mutation carriers (Papers I and 
II). We found a difference in cumulative lifetime risk of colorectal carcinoma between men 
and women. The results may be biased in different ways. The initial criteria for referral were 
clustering of CRC, which might have led to an overestimation of the risk of developing 
colorectal cancer. On the other hand, this should not influence the observed differences in 
developing cancer between the various groups of mutation carriers. Only patients who 
survived were available for mutation analysis, which might have led to an overrepresentation 
of cancers with a favourable prognosis. Environmental factors and modifying genes may have 
an influence. The potential effect of surveillance on cancers in the urinary tract and the 
endometrium was not examined.  
 
5.2 Amsterdam criteria II in combination with immunohistochemistry of the 
mismatch repair proteins in tumours may be a cost-effective approach to select families 
for mutation analysis. 
We went to Düsseldorf, Germany to learn more about IHC and to do a pilot study on IHC 
(Paper V). Results were encouraging, and we decided to validate screening of high risk 
groups with IHC on tumour tissue (Paper VI). The results show that applying the AMSII 
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increases the sensitivity and underlines that CRC can not be an obligatory requisite to define 
HNPCC. IHC is a functional test, demonstrating the transcription and translation of the gene 
as well as the presence of the gene product in proper concentration in the right place. 
Sensitivity and specificity is demonstrated to be good in high risk groups, but the method also 
has its obstacles. There is a logistical problem having to collect tumour blocks from various 
hospitals. We have reported on scoring problems, particularly in endometrial cancers (Paper 
IV). Old blocks might be fixated in ways that makes the quality of the staining poor. In our 
study, IHC of adenomas has not been a reliable tool to predict MMR mutations. Concurrent 
loss of MSH2 and MSH6 proteins makes distinction between underlying MSH2 and MSH6 
defects impossible. MLH1 promotor hypermethylation and loss of this protein creates a 
further problem. These problems might become more prominent if applying the method on 
sporadic cancers, but so far the method has not been validated in sporadic cancers in general. 
When mutation testing becomes more accessible or if there are populations with founder 
mutations one might choose to start directly with mutation analysis. 
 
In a large family we demonstrated that the inframe mutation in the family and lack of MSH2 
protein expression was associated with disease (Paper III). We had an extended pedigree and 
the possibility of examining several branches of the family. It is not clarified why an inframe 
deletion predicted to cause a protein short of one amino acid, is associated with the absence of 
the whole protein. It is possible that the protein was present, but not detected by the IHC 
method applied. Possibly more probable, the altered protein structure may have changed the 
functional properties of the protein, with the effect that it was not found in relevant 
concentrations where it should have been to exercise its function.  
 
5.3 MUTYH mutations do not cause HNPCC or late onset familial colorectal cancer. 
Families in our study without detected mutations in the MMR genes were tested to see if 
mutations in the MUTYH gene could explain the aggregation of cancers. (Paper VII). At the 
time we initiated our study, MUTYH, when mutated, was thought to cause a recessively 
inherited disorder including CRC. Later it has been debated whether heterozygous carriers of 
MUTYH may or may not have a slightly increased risk of CRC. It has also been demonstrated 
that the MSH2/MSH6 complex, active in MMR, is physically associated with MYH at an 
MSH6 binding site and is required to stimulate MYH activity. (Gu Y 2002, Bai H 2005). So 
much is still unknown regarding MUTYH that further studies are necessary. 
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5.4 Genetic work-up reduces input numbers to surveillance programs. 
We demonstrated that estimated prevalences of hereditary cancer and need for surveillance 
were dramatically reduced by a proper clinical genetic work-up (Paper VIII). Our prevalences 
were lower than what others have reported. Some of these reports were based on consecutive 
cancer series and others were done in populations known to have a high prevalence of founder 
mutations. Major draw backs were that our patients were part of a research population with 
older probands who may have had a limited motivation to provide family history and that 48 
persons were excluded due to previous CRC. Underreporting of cancers could not be 
addressed, as only claimed cases could (by legislation) initiate a search for conformation. On 
the other hand, persons at risk may be over-represented in screening programs.  
 
5.5 The low annual incidence rates for CRC in our study indicated that the removal 
of adenomas may have prevented cancers 
The observed results of follow-up colonoscopies done on our patients over the last 15 years 
indicated that the removal of adenomas may have prevented cancers (Paper IX).  
The strengths of the study were the nation-wide selection of CRC families, and a large 
number of persons at risk included. The limitation was the low prevalence of mutation carriers 
demonstrated, but this may reflect a low prevalence in our population. In families without a 
demonstrated mutation, all first degree relatives of affecteds were offered surveillance. 
Assuming autosomal dominant inheritance this means that half of the first degree relatives 
probably had a risk close to the population risk which would influence the annual incidence 
rates. Perhaps the observation time of colonoscopy screening is not long enough. The low 
number of cancers demonstrated was a finding. The low power of demonstrating a protective 
effect of an intervention is a general problem in studies like this and might not be a limitation 
specific to our study.  
 
5.6 Other comments 
Based on international consensus meetings, national collaboration and results from our 
studies, The Norwegian group on inherited cancer have made recommendations on handling 
inherited colorectal cancer (Møller et al., 2006). The recommendations are realistic with 
regard to what can be done within the structure of the Norwegian health service and 
Norwegian legislation.  
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Under Norwegian legislation, persons at risk should make the initial contact with the proper 
health personnel, and not vice versa. Consequently, other families may contain different 



































Based on current knowledge, including the reports in the present thesis, the genetic work-up 
of families suspected to have HNPCC was reformatted and now starts with 
immunohistochemistry of MMR gene products in tumours from affecteds, followed by 
mutation analyses of the genes not having a demonstrated gene product in the tumours. If a 
causative MMR mutation is found, predictive genetic testing is used as basis for preventive 
modalities. If no lack of gene products is found in tumours, the probability for HNPCC is low 
and the families will have to conform strictly to the Amsterdam criteria to be subjected to 
colonoscopy every second year from early adulthood. This has the effect of reducing work-
load for the health care system, reducing unsubstianted fear in the families, and providing 
rationale for better targeted preventive measures to the mutation carriers with respect to other 
expressions of the genetic defects, also considering the different expressions of the different 
genes when mutated. 
 
The low annual incidence rates for CRC in our study indicated that the removal of adenomas 
may have prevented cancers. This is an argument needed to continue the surveillance program 
in the mutation carriers, it is an information asked for by every patient, and it is to be included 
in any genetic counselling session to the families in question. 
 
A number of unresolved problems remain. A few of them are: Families without detected 
mutations indicate that there might be other genes involved that we still have not mapped. We 
have insufficient information on long-term strategies on how to handle the colon in those who 
have been prevented to die from colon cancer at an early age. We do not know whether or not 
continued surveillance is effective or if there should be a more systematic approach to 
undertake prophylactic colectomy. As more colorectal cancers are prevented or cured, we will 
obtain more information about the frequency and mortality of the other phenotypes. 
Surveillance, prevention and cure of these manifestations need to be evaluated. To gain 
knowledge on these subjects, we have to continue monitoring the families. Because of low 
numbers included at any clinical genetic centre, multi-centre collaboration to provide 
sufficient data sets for analyses is needed. Future handling of these patients calls for broad 
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